What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Portfolio Pulse from Vandana Singh
Guardant Health Inc (NASDAQ:GH) faces concerns from FDA staff reviewers regarding its experimental blood test for colorectal cancer, Shield, which may not detect some tumor types that could become cancerous. The FDA's Molecular and Clinical Genetics Panel will review the premarket approval application on May 23. Despite the concerns, the test's potential benefits in improving compliance and early detection were acknowledged. GH shares are down 2.62% at $24.12.
May 21, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Guardant Health's experimental blood test for colorectal cancer, Shield, faces concerns from FDA staff reviewers about its effectiveness in detecting certain tumor types. The FDA's Molecular and Clinical Genetics Panel will review the premarket approval application on May 23. Despite the concerns, the test's potential benefits were acknowledged. GH shares are down 2.62%.
The FDA's concerns about the effectiveness of Guardant Health's Shield test in detecting certain tumor types could delay or impact the approval process, negatively affecting investor sentiment. The stock has already dropped 2.62% in response to the news.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100